- $2.27bn
- $2.92bn
- $14.75m
- 38
- 10
- 44
- 19
Annual income statement for Immunitybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.605 | 0.934 | 0.24 | 0.622 | 14.7 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 14.7 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 221 | 331 | 352 | 363 | 359 |
| Operating Profit | -221 | -330 | -351 | -362 | -344 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -226 | -350 | -417 | -584 | -414 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -224 | -350 | -417 | -584 | -414 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -222 | -347 | -417 | -583 | -414 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -222 | -347 | -417 | -583 | -414 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.57 | -0.891 | -1.04 | -1.14 | -0.593 |